Aug
20
2026
Kynexis pockets €97m to advance cognition-focused schizophrenia drug
Dutch biotech Kynexis has banked €97m ($113m) through an extended Series A funding round, which the company will use to support the mid-to-late-stage development efforts for its lead cognitive …